Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations

Area of Science:

• Virology
• Drug Discovery
• Structural Biology

Background:

• Influenza outbreaks pose significant global health challenges, complicated by viral genetic polymorphism and vaccine development hurdles.
• Current treatments face limitations due to acquired resistance, necessitating novel therapeutic strategies.
• The M2 protein ion channel is crucial for influenza virus replication, making it a key target for antiviral therapies.

Purpose of the Study:

• To provide an overview of anti-influenza therapy, focusing on the M2 ion channel.
• To discuss the structure, function, and mechanism of the M2 protein and its role in viral replication.
• To highlight recently identified compounds with potential activity against wild-type and mutated M2 proteins.

Main Methods:

• Literature review of anti-influenza therapies and M2 protein research.
• Analysis of M2 protein structure and function in relation to viral replication.
• Identification and discussion of novel chemical scaffolds targeting M2 protein variants.

Main Results:

• Established M2 protein as a critical target for influenza A virus, essential for viral replication.
• Reviewed the mechanism of action for existing M2 inhibitors (amantadine, rimantadine) and their limitations due to resistance.
• Identified novel compound scaffolds demonstrating activity against both wild-type and resistant M2 protein variants.

Conclusions:

• The M2 protein remains a vital target for developing new anti-influenza agents.
• Existing M2 inhibitors are compromised by widespread resistance, underscoring the need for alternative treatments.
• Newly identified compounds targeting M2 protein offer promising alternatives for developing effective antibiotics against diverse influenza A virus strains.